A C5a receptor antagonist
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

PMX-53 (trifluoroacetate salt)

Item No. 35840

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
(6→2)-lactam, N-acetyl-L-phenylalanyl-L-ornithyl-L-prolyl-3-cyclohexyl-D-alanyl-L-tryptophyl-L-arginin, trifluoroacetate salt
CAS Number
514814-99-4
Synonyms
  • AcF-[OPdChaWR]
  • AcPhe-[Orn-Pro-D-Cyclohexylalanine-Trp-Arg]
  • 3D53
Molecular Formula
C47H65N11O7 • XCF3COOH
Formula Weight
896.1
Purity
≥95%
Formulation (Request formulation change)
A solid
Peptide Sequence
Ac-Phe[Orn-Pro-D-Cha-Trp-Arg]
Solubility(Learn about Variance in Solubility)
Water: Soluble
λmax
220 nm
SMILES
O=C([C@H](NC([C@@]1([H])N(CCC1)C([C@H](CCCNC([C@@H](NC2=O)CCCNC(N)=N)=O)NC([C@@H](NC(C)=O)CC3=CC=CC=C3)=O)=O)=O)CC4CCCCC4)N[C@H]2CC5=CNC6=CC=CC=C56.OC(C(F)(F)F)=O
InChi Code
InChI=1S/C47H65N11O7.C2HF3O2/c1-29(59)53-37(25-30-13-4-2-5-14-30)42(61)55-36-20-11-22-50-41(60)35(19-10-23-51-47(48)49)54-44(63)39(27-32-28-52-34-18-9-8-17-33(32)34)56-43(62)38(26-31-15-6-3-7-16-31)57-45(64)40-21-12-24-58(40)46(36)65;3-2(4,5)1(6)7/h2,4-5,8-9,13-14,17-18,28,31,35-40,52H,3,6-7,10-12,15-16,19-27H2,1H3,(H,50,60)(H,53,59)(H,54,63)(H,55,61)(H,56,62)(H,57,64)(H4,48,49,51);(H,6,7)/t35-,36-,37-,38+,39-,40-;/m0./s1
InChi Key
GLBSQYCQCYBLHZ-XRANFBFSSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $66

    Add

    5 mg

    $246

    Add

    10 mg

    $359

    Add

    25 mg

    $652

    Add
    Cayman Chemical
    Neutrophil Biology Wall Poster

    Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.

    DOWNLOAD NOW
    Product Description

    PMX-53 is a macrocyclic complement 5a (C5a) peptidomimetic and an antagonist of the C5a receptor (IC50 = 0.3 µM).1 It inhibits C5a-induced secretion of myeloperoxidase (MPO) in isolated human polymorphonuclear leukocytes (PMNs). PMX-53 (10 mg/kg, p.o.) inhibits vascular leakage, PMN infiltration, and peritoneal TNF-α and IL-6 production in a rat model of the peritoneal Arthus reaction.1 It reduces body weight loss and anorexia and inhibits striatal degeneration in a rat model of Huntington’s disease induced by 3-nitropropionic acid (3-NP; Item No. 14684).2 PMX-53 (3 mg/kg) also reduces atherosclerotic lesion size and lipid content in ApoE-/- mice.3

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Finch, A.M., Wong, A.K., Paczkowski, N.J., et al. Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a. J. Med. Chem. 42(11), 1965-1974 (1999).

    2. Woodruff, T.M., Crane, J.W., Proctor, L.M., et al. Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration. FASEB J. 20(9), 1407-1417 (2006).

    3. Manthey, H.D., Thomas, A.C., Shiels, I.A., et al. Complement C5a inhibition reduces atherosclerosis in ApoE-/- mice. FASEB J. 20(9), 1407-1417 (2011).